Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO TAT 2023 | Avelumab and talazoparib in BRCA1/2- or ATM-mutant solid tumors

Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of findings from the Phase IIb JAVELIN BRCA/ATM study (NCT03565991) of avelumab and talazoparib, a PARP inhibitor, in patients with BRCA1/2- or ATM-altered advanced solid tumors. Patients were divided based on the presence of BRCA1/2 or ATM mutations and the primary endpoint was objective response rate (ORR). Despite a favorable safety profile, the primary endpoint was not met. This interview took place at the ESMO Targeted Anticancer Therapies (TAT) Congress 2023 in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.